Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose. Results from OVATION 2 Study continue ...
Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...
Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
YourBio Health, a pioneer in remote blood collection technology, announced today the appointments of Michael Mina, M.D., Ph.D. as Chief Scientific Officer, Chester Robson D.O., as Chief Medical ...
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback